First Light Asset Management LLC Has $7.26 Million Holdings in TransMedics Group, Inc. $TMDX

Key Points

• First Light Asset Management LLC reduced its position in TransMedics Group, Inc. by 22.8%, owning 107,860 shares valued at approximately $7.26 million.
• TransMedics reported a significant quarterly EPS of $0.92, exceeding analysts' estimates and showing a 37.7% increase in revenue compared to the previous year.
• Brokerages are optimistic about TransMedics, with an average price target of $123.00 and ratings ranging from "Strong Buy" to "Hold" among investment analysts.

First Light Asset Management LLC decreased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 22.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 107,860 shares of the company's stock after selling 31,897 shares during the period. TransMedics Group comprises 0.8% of First Light Asset Management LLC's portfolio, making the stock its 27th biggest position. First Light Asset Management LLC owned about 0.32% of TransMedics Group worth $7,257,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. NBC Securities Inc. bought a new stake in shares of TransMedics Group during the first quarter valued at approximately $25,000. Smartleaf Asset Management LLC boosted its position in TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after buying an additional 135 shares during the last quarter. Quarry LP boosted its position in TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after buying an additional 278 shares during the last quarter. Hager Investment Management Services LLC increased its stake in shares of TransMedics Group by 38.3% in the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after buying an additional 205 shares during the period. Finally, CWM LLC raised its position in shares of TransMedics Group by 20.1% during the first quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after acquiring an additional 155 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at TransMedics Group

In other news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the sale, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 7.00% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on TMDX. Morgan Stanley upped their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Stifel Nicolaus began coverage on shares of TransMedics Group in a research report on Thursday. They issued a "hold" rating and a $115.00 price objective for the company. Wall Street Zen downgraded TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Oppenheimer increased their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Finally, Canaccord Genuity Group increased their target price on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $122.11.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX traded down $0.04 on Friday, hitting $104.01. The company had a trading volume of 996,736 shares, compared to its average volume of 877,429. The stock has a 50 day moving average price of $118.07 and a 200 day moving average price of $104.09. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of 53.91 and a beta of 2.18. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $169.29.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. TransMedics Group's quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. Analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.